Warning: The NCBI web site requires JavaScript to function. more...
Aptamer-targeted cell-specific RNA interference.
Zhou J, Rossi JJ.
Silence. 2010 Feb 1;1(1):4.
Related citations
The therapeutic potential of cell-internalizing aptamers.
Curr Top Med Chem. 2009;9(12):1144-57.
Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery.
Zhou J, Li H, Zhang J, Piotr S, Rossi J.
J Vis Exp. 2011 Jun 23;(52). pii: 2954. doi: 10.3791/2954.
Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition.
Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ.
Methods. 2011 Jun;54(2):284-94. Epub 2011 Jan 20.
Cell-specific aptamer-mediated targeted drug delivery.
Oligonucleotides. 2011 Feb;21(1):1-10. Epub 2010 Dec 23. Review.
Intracellular delivery of RNA-based therapeutics using aptamers.
Thiel KW, Giangrande PH.
Ther Deliv. 2010 Dec 1;1(6):849-861.
Aptamer-targeted RNAi for HIV-1 therapy.
Methods Mol Biol. 2011;721:355-71.
Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH.
Nat Biotechnol. 2006 Aug;24(8):1005-15. Epub 2006 Jun 25.
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A.
Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. Epub 2010 Nov 18. Review.
Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S.
Curr Cancer Drug Targets. 2008 Nov;8(7):554-65.
Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
Liu B.
Brief Funct Genomic Proteomic. 2007 Jun;6(2):112-9. Epub 2007 Jul 31. Review.
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
DeVincenzo JP.
Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. Epub 2009 Oct 14.
Aptamer applications for targeted cancer therapy.
Barbas AS, Mi J, Clary BM, White RR.
Future Oncol. 2010 Jul;6(7):1117-26. Review.
Chimeric aptamers in cancer cell-targeted drug delivery.
Kanwar JR, Roy K, Kanwar RK.
Crit Rev Biochem Mol Biol. 2011 Dec;46(6):459-77. doi: 10.3109/10409238.2011.614592. Epub 2011 Sep 28.
RNAi-based therapeutic strategies for metabolic disease.
Czech MP, Aouadi M, Tesz GJ.
Nat Rev Endocrinol. 2011 Apr 19;7(8):473-84. doi: 10.1038/nrendo.2011.57. Review.
Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4.
Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ.
Gene Ther. 2004 Dec;11(23):1703-12.
Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.
Aigner A.
J Biomed Biotechnol. 2006;2006(4):71659.
[Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V.
Wien Med Wochenschr. 2006 Sep;156(17-18):481-7. Review. German.
Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
J Biotechnol. 2006 Jun 25;124(1):12-25. Epub 2006 Jan 18. Review.
Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics.
Pangburn TO, Petersen MA, Waybrant B, Adil MM, Kokkoli E.
J Biomech Eng. 2009 Jul;131(7):074005. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on